DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Estring (Estradiol Vaginal Ring) - Published Studies

 
 



Estring Related Published Studies

Well-designed clinical trials related to Estring (Estradiol Vaginal Ring)

Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study. [2010.09]

Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. [2007.06]

Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. [2006.12]

Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. [2006.09]

Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables. [2006.07]

Clinical performance and menstrual bleeding patterns with three dosage combinations of a Nestorone progestogen/ethinyl estradiol contraceptive vaginal ring used on a bleeding-signaled regimen. [2005.07]

Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen. [2005.07]

Vaginal ring delivering estradiol and progesterone: a possible alternative to relieve climacteric symptoms. [2005.05]

Bone mineral density in postmenopausal women treated with a vaginal ring delivering systemic doses of estradiol acetate. [2005.05]

Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. [2005.03]

Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. [2005.02]

Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. [2003.10]

The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women. [2003.08]

Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms. [2003.06]

Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women. [2003.01]

Endometrial thickness and uterine diameter not affected by ultralow doses of 17beta-estradiol in elderly women. [2002.05]

Serum lipid profile improved by ultra-low doses of 17 beta-estradiol in elderly women. [2001.06]

Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. [2000.09]

Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. [2000.08]

A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. [1999.05]

A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol. [1999.05]

Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Vaginal Ring Study Group. [1999]

[Continuous, low dosage estradiol administration with a vaginal ring: a placebo-controlled study] [1998]

Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. [1997.01]

A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response. [1996.11]

Intrauterine or oral administration of levonorgestrel in combination with estradiol to perimenopausal women--effects on lipid metabolism during 12 months of treatment. [1996.09]

A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. [1996.04]

A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. [1996.01]

Pharmacokinetic data on estradiol in light of the estring concept. Estradiol and estring pharmacokinetics. [1996]

Clinical trial of the estradiol vaginal ring in the U.S. [1995.12]

The estradiol vaginal ring--a study of existing clinical data. [1995.12]

Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. [1995.02]

A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy. [1994.09]

Studies on a vaginal ring releasing levonorgestrel at an initial rate of 27 micrograms/24 h when used alone or in combination with transdermal systems releasing estradiol. [1994.07]

Effects and acceptability of a new 17 beta-oestradiol-releasing vaginal ring in the treatment of postmenopausal complaints. [1993.09]

Intracervical 17 beta-oestradiol before induction of second-trimester abortion with a prostaglandin E1 analogue. [1989.08]

Well-designed clinical trials possibly related to Estring (Estradiol Vaginal Ring)

A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. [2011.02]

Vaginal estrogen supplementation during Depo-Provera initiation: a randomized controlled trial. [2010.09]

Effect on carbohydrate metabolism and analysis of acceptability (menstrual cycle control) of extended regimens of the vaginally inserted hormone-releasing system 'NuvaRing' as compared with the standard 21/7 regime in reproductive-age women with type 1 diabetes mellitus. [2010.09]

Adherence and acceptability of the contraceptive ring compared with the pill among students: a randomized controlled trial. [2010.03]

Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study. [2010.03]

Sexual function in first-time contraceptive ring and contraceptive patch users. [2010.01]

[Combined hormonal contraception in cycles artificially extended]. [2010.01]

Route of administration of contraceptives containing desogestrel/etonorgestrel and insulin sensitivity: a prospective randomized study. [2009.07]

Letrozole administration during the luteal phase after ovarian stimulation impacts corpus luteum function: a randomized, placebo-controlled trial. [2009.07]

A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. [2009.04]

Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial. [2008.09]

Use of the NuvaRing(R) hormone-releasing system in late reproductive-age women with type 1 diabetes mellitus. [2008.02]

Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. [2006.09]

A prospective trial comparing oocyte donor ovarian response and recipient pregnancy rates between suppression with gonadotrophin-releasing hormone agonist (GnRHa) alone and dual suppression with a contraceptive vaginal ring and GnRH. [2006.08]

A trial of contraceptive methods in women with systemic lupus erythematosus. [2005.12.15]

Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive. [2005.11]

Extended regimens of the contraceptive vaginal ring: a randomized trial. [2005.09]

Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive. [2005.07]

Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials. [2005]

Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study. [2004.11]

A comparative study on the effects of a contraceptive vaginal ring NuvaRing and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function. [2004.09]

A comparison between the vaginal ring and oral contraceptives. [2004.09]

The combined contraceptive vaginal ring, NuvaRing, and tampon co-usage. [2004.03]

The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication. [2004.02]

A randomized controlled trial of hysterectomy or levonorgestrel-releasing intrauterine system in the treatment of menorrhagia-effect on FSH levels and menopausal symptoms. [2004.02]

Continuous intrauterine compared with cyclic oral progestin administration in perimenopausal HRT. [2003.09.25]

The combined contraceptive ring NuvaRing and spermicide co-medication. [2003.04]

Ovarian function with a novel combined contraceptive vaginal ring. [2002.10]

Emergency contraception. [2002.08.06]

Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. [2002.02]

[Clinical study on women with amenorrhea after levonorgestrel intrauterine system] [2001.11]

Ovarian function during use of vaginal rings delivering three different doses of Nestorone. [2001.05]

Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. [2001.05]

Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation. [2000.10]

Premenopause contraception with monthly injectable Mesigyna with special emphasis on serum lipid and bone density patterns. [2000.05]

Plasma insulin-like growth factor-I and its binding proteins 1 and 3 during continuous nonoral and oral combined hormone replacement therapy. [1998.01]

Effect of different insertion regimens on side effects with a combination contraceptive vaginal ring. [1997.10]

Intrauterine administration of levonorgestrel 5 and 10 microg/24 hours in perimenopausal hormone replacement therapy. A randomized clinical study during one year. [1997.05]

Intrauterine administration of levonorgestrel in two low doses in HRT. A randomized clinical trial during one year: effects on lipid and lipoprotein metabolism. [1995.11]

Serum lipids and lipoproteins in postmenopausal women receiving transdermal oestrogen in combination with a levonorgestrel-releasing intrauterine device. [1995.06]

The effect of small doses of progesterone released from two types of vaginal rings on ovarian activity and bleeding patterns during the first postpartum year. [1995.04]

Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. [1995.01]

Lipid and biochemical changes after low-dose oral contraception. [1992.09]

Intrauterine release of levonorgestrel--a new way of adding progestogen in hormone replacement therapy. [1992.06]

Serum lipid variations in women on copper intrauterine devices, triphasic oral contraceptives and monthly injectable contraceptives. [1991.09]

Effects of various IUDs on the composition of cervical mucus. [1991.05]

Pharmacodynamics of a contraceptive vaginal ring releasing 3-keto-desogestrel. [1989.06]

Estrogen-progestogen once-a-month injectable contraceptives and serum prolactin. [1989.05]

A multicentre comparative study of serum lipids and lipoproteins in four groups of oral combined contraceptive users and a control group of IUD users. World Health Organization. Task Force on Oral Contraceptives. [1988.12]

The effects of three different regimens of oral contraceptives and three different intrauterine devices on the levels of hemoglobin, serum iron and iron binding capacity in anemic women. [1983.03]

Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring. [1980.04.01]

Other research related to Estring (Estradiol Vaginal Ring)

Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. [2012]

Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. [2011.09]

Extended regimens of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: effects on lipid metabolism. [2011.08]

Differential regulation of estrous behavior and luteinizing hormone secretion by estradiol-17beta in ovariectomized dairy cows. [2011.01.15]

Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. [2011]

Cerebral venous sinus thrombosis in a woman using the etonogestrel-ethinyl estradiol vaginal contraceptive ring: a case report. [2010.03]

Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study. [2010]

The combined etonogestrel/ethinyl estradiol contraceptive vaginal ring. [2007.08]

Effects of oral and trans-vaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, cross-over study. [2007.03.20]

High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol. [2007]

Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive. [2006.01]

Feasibility study of Nestorone(R)-ethinylestradiol vaginal contraceptive ring for emergency contraception. [2006.01]

Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. [2005.09]

Low-dose intravaginal estradiol delivery using a Silastic vaginal ring for estrogen replacement therapy in postmenopausal women: a review. [2003.12]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017